Nutriband Inc. (NTRB)
5.33
0.10 (1.91%)
At close: Apr 24, 2025, 12:12 PM
1.91% (1D)
| Bid | 5.28 |
| Market Cap | 59.2M |
| Revenue (ttm) | 2.02M |
| Net Income (ttm) | -6.85M |
| EPS (ttm) | -0.71 |
| PE Ratio (ttm) | -7.51 |
| Forward PE | -9.07 |
| Analyst | Buy |
| Ask | 5.43 |
| Volume | 6,314 |
| Avg. Volume (20D) | 75,018 |
| Open | 5.28 |
| Previous Close | 5.23 |
| Day's Range | 5.28 - 5.63 |
| 52-Week Range | 3.30 - 11.78 |
| Beta | 0.91 |
About NTRB
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; e...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 1, 2021
Employees 13
Stock Exchange NASDAQ
Ticker Symbol NTRB
Website https://nutriband.com
Analyst Forecast
According to 1 analyst ratings, the average rating for NTRB stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 143.90% from the latest price.
Stock Forecasts2 months ago
+17.09%
Nutriband shares are trading higher after the comp...
Unlock content with
Pro Subscription
3 months ago
+40.88%
Nutriband shares are trading higher after Noble Capital Markets initiated coverage on the stock with an Outperform rating and a $13 price target.